undamentalytics Newsletter
Sign in

Natural Alternatives International Inc (NAII) stock

Add to watchlist

Add holding +

NASDAQ: NAII Nasdaq Pharmaceuticals

C+ Fundamentals grade

Natural Alternatives International Inc is a US-listed company in the pharmaceuticals industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: share count (6m) is 0.28x the cover-page count (22m).

Price vs value

Under review: share count (6m) is 0.28x the cover-page count (22m). We'll show the comparison once resolved.

Natural Alternatives International Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling14 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds7 adding, 8 cuttingOf 3 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Natural Alternatives International files

Where Natural Alternatives International stands after its latest 10-K

Revenue for the twelve months to June 2026 was $143m, up 9.7% on a year earlier, slower than the 13.1% growth a quarter earlier. Free-cash-flow margin fell to -8.9% from 1.8% a year earlier. Operating margin narrowed to -13.2% from -6.7%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 3 of our 6 financial-health checks.

Our model value for Natural Alternatives International is under review, so past values are not shown until it is resolved.

Source: 10-K filed September 28, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Natural Alternatives International Inc's trailing-twelve-month revenue grew 9.7% year on year, with a free-cash-flow margin of -8.9%. Where it stands out: stock pay as % of revenue of 0.4% ranks 4 of 69 pharmaceuticals companies we cover. Where it lags: gross margin of 6.3% ranks 57 of 59 pharmaceuticals companies we cover.

Current signal Operating margin compressing: TTM operating margin fell to -13.2%, down 6.5pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Natural Alternatives International Inc's latest figures clears our strength thresholds.

Things to watch

  • Loss-making. Operating margin is -13.2%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 6.5 points on a year ago.
  • Burning cash. Free cash flow was -8.9% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 65% and a beta of 0.8 against the S&P 500.
  • Growth easing. The growth rate is 3.3 points lower than a quarter earlier.
  • Below peers: gross margin. Gross margin of 6.3% ranks 57 of 59 pharmaceuticals companies we cover (median 59.8%).

Latest results: FY2026 Q4

Filed September 28, 2026
Revenue
$35m, up 1.9% on a year earlier

Natural Alternatives International's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day0.0%
  • 1 week-7.0%
  • 1 month-27.7%
  • This year-70.1%
  • 1 year-60.8%
  • 5 years-91.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$143M
Operating margin
-13.2%
Net margin
-14.5%
EPS (TTM, diluted)
$-3.43

Growth

Revenue growth
+9.7%
Change in growth rate
−3.3 pts
Share count change
+1.4%

Cash

Free cash flow (TTM)
-$12.6M
FCF margin
-8.9%
Stock pay % of revenue
0.4%

Earnings

Last results
September 22, 2008

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for NAII from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Natural Alternatives International Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: share count (6m) is 0.28x the cover-page count (22m): held for review.

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026
Share price$11.04$9.95$10.15$11.66$6.84$16.83$10.44$7.20$6.02$3.28$2.39
Market value$73m$66m$70m$83m$46m$107m$64m$42m$35m$20m$14m
+ Net debt (− = net cash)−$20m−$28m−$24m−$25m−$20m−$32m−$12m−$4m$352000−$2m$11m
Enterprise value$54m$38m$46m$58m$25m$75m$52m$38m$36m$18m$25m
Multiples
Price / sales 0.6x0.5x0.5x0.6x0.4x0.6x0.4x0.3x0.3x0.2x0.1x
Price / earnings 7.7x9.2x13.8x12.7x—10.0x6.0x16.8x———
Price / free cash flow —7.5x—66.9x—6.8x———8.4x—
EV / EBITDA 3.8x3.2x3.7x6.1x10.3x4.2x2.9x4.3x———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

27 /100

Weak moat

How hard Natural Alternatives International's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 5 / 20

    Cash operating profit has been a median 5.4% of total assets over 9 years.

  • Pricing power 5 / 20

    Gross margin has been a median 16.5%, moving by 5.5 percentage points (standard deviation) across 10 years.

  • Durability 0 / 20

    Operating margin has been a median 3.7%; its worst year was -13.2%.

  • Cash conversion 4 / 20

    Free cash flow was positive in 4 of 10 years, at a median -1.7% of revenue.

  • Discipline 19 / 20

    The diluted share count fell 5.5% over five years; stock-based pay has been a median 0.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (32 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Natural Alternatives International Inc: too few analysts cover it.

Management guidance

Earnings release, September 22, 2008

No numeric guidance in Natural Alternatives International Inc's latest earnings release (filed September 22, 2008). Some companies give their outlook only on the earnings call.

Positioning

Short interest
0.1%
of tradable shares
Days to cover
0.15
at average volume
Short interest, 1 month
−67%
to October 15, 2026
Held by institutions
36%
of shares
Held by insiders
21.4%
of shares
Employees
301
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −60.8%

$2.73 on October 31, 2025 to $1.07

ThenNowEffect
Revenue (last 12 months) $130m $143m +9.7%
P/S multiple 0.1x 0.0x −63.8%
Share count 6m 6m −1.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −82.5%

$6.13 on November 3, 2023 to $1.07

ThenNowEffect
Revenue (last 12 months) $154m $143m −7.5%
P/S multiple 0.2x 0.0x −80.7%
Share count 6m 6m −2.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
NAII+20%−34%−22%−34%−17%−70%
Industry peers (median)−20%−52%−13%−2%+9%−12%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
NAII42%42%42%42%33%18%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
NAII−35%−47%−45%−40%−40%−78%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 94% from August 5, 2021 to October 30, 2026. Getting back needed a 1690% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.07 – $4.83
From 52-week high
−77.8%
vs 50-day average
−33.6%
vs 200-day average
−56.1%
Volatility (1 year)
65%
Beta vs S&P 500
0.83

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Natural Alternatives International Inc in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Natural Alternatives International Inc
$110M $120M $130M $140M $150M FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Revenue (TTM), FY24 Q1: $144.9M Revenue (TTM), FY24 Q2: $127.8M Revenue (TTM), FY24 Q3: $120.2M Revenue (TTM), FY24 Q4: $113.8M Revenue (TTM), FY25 Q1: $113M Revenue (TTM), FY25 Q2: $121.9M Revenue (TTM), FY25 Q3: $125.5M Revenue (TTM), FY25 Q4: $129.9M Revenue (TTM), FY26 Q1: $134.4M Revenue (TTM), FY26 Q2: $135.2M Revenue (TTM), FY26 Q3: $141.9M Revenue (TTM), FY26 Q4: $142.5M $142.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q1 $144.9M
FY24 Q2 $127.8M
FY24 Q3 $120.2M
FY24 Q4 $113.8M
FY25 Q1 $113M
FY25 Q2 $121.9M
FY25 Q3 $125.5M
FY25 Q4 $129.9M
FY26 Q1 $134.4M
FY26 Q2 $135.2M
FY26 Q3 $141.9M
FY26 Q4 $142.5M
Revenue growth, TTM YoY Natural Alternatives International Inc
-40% -20% 0% 20% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Revenue growth, TTM YoY, FY24 Q1: -17.6% Revenue growth, TTM YoY, FY24 Q2: -29.1% Revenue growth, TTM YoY, FY24 Q3: -29.6% Revenue growth, TTM YoY, FY24 Q4: -26.1% Revenue growth, TTM YoY, FY25 Q1: -22.0% Revenue growth, TTM YoY, FY25 Q2: -4.6% Revenue growth, TTM YoY, FY25 Q3: 4.4% Revenue growth, TTM YoY, FY25 Q4: 14.1% Revenue growth, TTM YoY, FY26 Q1: 19.0% Revenue growth, TTM YoY, FY26 Q2: 10.9% Revenue growth, TTM YoY, FY26 Q3: 13.1% Revenue growth, TTM YoY, FY26 Q4: 9.7% 9.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q1 -17.6%
FY24 Q2 -29.1%
FY24 Q3 -29.6%
FY24 Q4 -26.1%
FY25 Q1 -22.0%
FY25 Q2 -4.6%
FY25 Q3 4.4%
FY25 Q4 14.1%
FY26 Q1 19.0%
FY26 Q2 10.9%
FY26 Q3 13.1%
FY26 Q4 9.7%
Operating margin (TTM) Natural Alternatives International Inc
-15% -10% -5% 0% 5% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Operating margin (TTM), FY24 Q1: 1.8% Operating margin (TTM), FY24 Q2: -2.6% Operating margin (TTM), FY24 Q3: -2.4% Operating margin (TTM), FY24 Q4: -7.5% Operating margin (TTM), FY25 Q1: -8.7% Operating margin (TTM), FY25 Q2: -7.5% Operating margin (TTM), FY25 Q3: -7.4% Operating margin (TTM), FY25 Q4: -6.7% Operating margin (TTM), FY26 Q1: -4.9% Operating margin (TTM), FY26 Q2: -4.1% Operating margin (TTM), FY26 Q3: -5.3% Operating margin (TTM), FY26 Q4: -13.2% -13.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q1 1.8%
FY24 Q2 -2.6%
FY24 Q3 -2.4%
FY24 Q4 -7.5%
FY25 Q1 -8.7%
FY25 Q2 -7.5%
FY25 Q3 -7.4%
FY25 Q4 -6.7%
FY26 Q1 -4.9%
FY26 Q2 -4.1%
FY26 Q3 -5.3%
FY26 Q4 -13.2%
FCF margin (TTM) Natural Alternatives International Inc
-15% -10% -5% 0% 5% 10% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 FCF margin (TTM), FY24 Q1: 6.2% FCF margin (TTM), FY24 Q2: 3.6% FCF margin (TTM), FY24 Q3: 5.4% FCF margin (TTM), FY24 Q4: -4.0% FCF margin (TTM), FY25 Q1: -10.2% FCF margin (TTM), FY25 Q2: -10.2% FCF margin (TTM), FY25 Q3: -2.6% FCF margin (TTM), FY25 Q4: 1.8% FCF margin (TTM), FY26 Q1: 0.8% FCF margin (TTM), FY26 Q2: -3.9% FCF margin (TTM), FY26 Q3: -6.4% FCF margin (TTM), FY26 Q4: -8.9% -8.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q1 6.2%
FY24 Q2 3.6%
FY24 Q3 5.4%
FY24 Q4 -4.0%
FY25 Q1 -10.2%
FY25 Q2 -10.2%
FY25 Q3 -2.6%
FY25 Q4 1.8%
FY26 Q1 0.8%
FY26 Q2 -3.9%
FY26 Q3 -6.4%
FY26 Q4 -8.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Jun 2011 2012 Jun 2012 2013 Jun 2013 2014 Jun 2014 2015 Jun 2015 2016 Jun 2016 2017 Jun 2017 2018 Jun 2018 2019 Jun 2019 2020 Jun 2020 2021 Jun 2021 2022 Jun 2022 2023 Jun 2023 2024 Jun 2024 2025 Jun 2025 2026 Jun 2026
Income
Revenue 56 73 63 74 80 114 122 132 138 119 179 171 154 114 130 143
Gross profit 11 15 12 13 14 25 26 26 24 19 30 31 18 7 9 9
EBITDA 6 9 5 6 7 14 12 12 9 2 18 18 9 −4 −4 −14
Operating income 2 6 2 3 4 12 10 10 6 −2 14 14 5 −9 −9 −19
Net income 5 4 2 2 3 10 7 5 7 −2 11 11 3 −7 −14 −21
Diluted EPS $0.71 $0.59 $0.23 $0.29 $0.49 $1.44 $1.09 $0.73 $0.92 −$0.25 $1.69 $1.74 $0.43 −$1.23 −$2.28 −$3.43
Growth (year on year)
Revenue — +30.3% −13.8% +17.7% +7.5% +43.6% +6.8% +8.6% +4.4% −14.0% +50.2% −4.2% −9.9% −26.1% +14.1% +9.7%
EBITDA — +66.1% −43.7% +9.5% +16.0% +112.9% −13.9% +2.9% −24.2% −74.0% +635.1% −0.9% −49.8% −143.4% — —
Operating income — +166.7% −65.3% +29.0% +49.8% +194.7% −20.9% −1.7% −37.5% −125.3% — +0.1% −65.5% −281.1% — —
Net income — −18.2% −62.2% +27.0% +67.8% +185.3% −24.2% −30.2% +29.5% −125.1% — −0.5% −76.5% — — —
Diluted EPS — −16.9% −61.0% +26.1% +69.0% +193.9% −24.3% −33.0% +26.0% −127.2% — +3.0% −75.3% — — —
Margins
Gross margin 19.0% 21.2% 19.3% 17.2% 18.0% 22.1% 21.5% 19.9% 17.0% 15.9% 17.1% 17.8% 11.8% 6.0% 7.2% 6.3%
EBITDA margin 9.9% 12.7% 8.3% 7.7% 8.3% 12.3% 9.9% 9.4% 6.8% 2.1% 10.1% 10.4% 5.8% −3.4% −3.2% −9.9%
Operating margin 4.2% 8.5% 3.4% 3.8% 5.2% 10.7% 8.0% 7.2% 4.3% −1.3% 7.7% 8.0% 3.1% −7.5% −6.7% −13.2%
Net margin 9.1% 5.7% 2.5% 2.7% 4.2% 8.4% 5.9% 3.8% 4.7% −1.4% 6.0% 6.3% 1.6% −6.3% −10.5% −14.5%
Free-cash-flow margin 13.2% −0.8% 4.5% 3.6% 1.2% −1.0% 7.2% −1.7% 0.9% −0.7% 8.8% −8.6% −4.2% −4.0% 1.8% −8.9%
Cash flow
Cash from operations 9 2 4 5 3 9 14 2 7 4 21 12 7 −1 6 −9
Capital spending 2 2 2 3 2 10 5 4 5 5 5 26 14 3 4 4
Free cash flow 7 −1 3 3 1 −1 9 −2 1 −1 16 −15 −7 −5 2 −13
Stock-based pay 0 0 0 0 0 1 1 1 2 2 1 1 1 1 1 1
Free cash flow after stock pay 7 −1 3 2 1 −2 8 −4 −0 −3 14 −16 −8 −6 1 −13
Balance sheet
Cash 15 14 17 20 19 20 28 24 25 30 32 22 14 12 12 7
Total debt 0 0 0 0 0 0 0 0 — 10 0 10 10 12 11 18
Net debt (negative = net cash) −15 −14 −17 −20 −19 −20 −28 −24 −25 −20 −32 −12 −4 0 −2 11
Diluted shares 7m 7m 7m 7m 7m 7m 7m 7m 7m 7m 6m 6m 6m 6m 6m 6m
Returned to shareholders
Buybacks 0 0 1 0 2 1 1 1 1 4 4 6 2 0 0 0
Total returned 0 0 1 0 2 1 1 1 1 4 4 6 2 0 0 0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $126m
Short-term assets $65mLonger-term assets $61m
What it owes, and who funded it · $126m
Short-term liabilities $38mLonger-term liabilities $39mShareholders' equity $50m
  • Short-term assets cover short-term liabilities $65m of assets due within a year against $38m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $65m short-term assets against $39m of longer-dated liabilities.
  • More cash than debt $7m of cash against $10m of debt.
  • Debt below 40% of shareholders' equity Debt is 20% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 11% to 20% over five years.
  • A year's operating cash flow covers at least 20% of debt −$9m of operating cash flow against $10m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Natural Alternatives International Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q4 TTM
Buybacks (TTM)
$89,000
Returned to shareholders
-1%
of free cash flow
Buybacks, last 3 fiscal years
$488,000
Diluted share count
+1.4%
year over year
Total shareholder yield
1.3%
dividends 0.0% + buybacks 1.3% of market value
Days sales outstanding
53 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated NAII ZVRA HRTX NAGE AMRN CRON Median
Revenue, last 12 months $143m $136m $151m $129m $176m $179m $276m
Revenue growth, last 12 months 9.7% 119.4% 1.0% 11.0% −22.3% 37.5% 9.9%
Revenue growth, 3-year average −2.6% 101.9% 8.6% 16.8% −18.3% 30.3% 5.5%
Revenue growth, latest quarter 1.9% 53.3% 1.3% −4.3% −20.4% 58.4% 6.5%
Gross margin 6.3% 89.3% 70.1% 64.2% 40.9% 45.9% 62.0%
Operating margin −13.2% 60.5% −7.2% 8.2% −18.2% −1.4% −5.9%
Operating margin, 3-year average −9.1% −149.1% −13.5% 6.6% −26.3% −38.9% −7.4%
Net margin −14.5% 42.8% −22.5% 12.4% −10.9% 39.1% −7.3%
Cash from operations / revenue −6.3% 24.5% −7.7% 4.6% 21.3% 33.5% 10.2%
Free-cash-flow margin −8.9% 24.0% −8.0% 4.2% 21.3% 27.8% 8.6%
Free-cash-flow margin, 3-year average −3.7% −96.2% −47.0% 7.4% 1.3% 11.1% 7.4%
Stock pay / revenue 0.4% 9.6% 7.4% 5.4% 4.2% 3.6% 3.6%
Change in share count 1.4% 13.4% 5.9% 2.5% 1.5% −2.1% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 9.7% 10.0% 38 of 74
Change in growth rate Growth -3.3pp -0.3pp 48 of 74
Gross margin Profitability 6.3% 59.8% 57 of 59
Operating margin Profitability -13.2% -5.9% 37 of 67
Net margin Profitability -14.5% -7.3% 46 of 75
Free-cash-flow margin Cash generation -8.9% 10.1% 52 of 74
Stock pay as % of revenue Cash generation 0.4% 3.6% 4 of 69
Long-term debt as % of assets Balance sheet 8.1% 23.8% 13 of 53
Change in share count Balance sheet 1.4% 1.5% 30 of 62
Days sales outstanding Balance sheet 53 days 72 days 15 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to June 30, 2026
Segments
Line of business Revenue Share YoY
Private Label Contract Manufacturing $135M 94.5% ▲ 10.5%
Patent and Trademark Licensing $7.9M 5.5% ▼ 2.2%
Geography
Region Revenue Share YoY
United States $93.3M 65.5% ▲ 17.9%
Outside the US $49.2M 34.5% ▼ 3.0%

From Natural Alternatives International Inc's 10-K filed September 28, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$5.5M
Institutions reporting
23
Shares held vs prior quarter
▲ 5.9%
Positions opened / closed
3 / 1

Top buyers and sellers, Q2 2026: 7 institutions bought and 8 sold ; the biggest buyer was Integrated Wealth Concepts LLC (+76K shares) and the biggest seller Dimensional Fund Advisors LP (−19K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Caldwell Sutter Capital, Inc. $1.2M 498K 21.5% ▼ 0.1%
Dimensional Fund Advisors LP $802,536 336K 14.5% ▼ 5.3%
Morgan Stanley $735,236 308K 13.3% ▲ 14.7%
Mink Brook Asset Management LLC $701,338 293K 12.6% ▼ 0.1%
Renaissance Technologies LLC $663,122 277K 12.0% ▼ 4.8%
Vanguard Capital Management LLC $504,003 211K 9.1% 0.0%
Integrated Wealth Concepts LLC $210,764 88K 3.8% ▲ 634.9%
Citadel Advisors LLC $181,033 76K 3.3% ▲ 73.3%
Bridgeway Capital Management, LLC $146,973 61K 2.7% ▼ 18.4%
Geode Capital Management, LLC $104,504 44K 1.9% ▼ 16.6%
Vanguard Fiduciary Trust Co $64,757 27K 1.2% 0.0%
Empowered Funds, LLC $59,525 25K 1.1% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Natural Alternatives International Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $26,844 14 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $26,844 net buying
Insider Date Trade Shares Price Value
Ledoux Mark A CEO/Chairman March 6, 2026 Buy 532 $2.80 $1,490
Ledoux Mark A CEO/Chairman March 5, 2026 Buy 218 $2.75 $600
Ledoux Mark A CEO/Chairman March 4, 2026 Buy 500 $2.77 $1,385
Ledoux Mark A CEO/Chairman March 2, 2026 Buy 500 $2.79 $1,395
Ledoux Mark A CEO/Chairman February 27, 2026 Buy 250 $2.80 $700
Ledoux Mark A CEO/Chairman February 27, 2026 Buy 500 $2.85 $1,425
Ledoux Mark A CEO/Chairman February 26, 2026 Buy 500 $2.85 $1,425
Ledoux Mark A CEO/Chairman February 25, 2026 Buy 500 $2.81 $1,405
Ledoux Mark A CEO/Chairman February 24, 2026 Buy 1,000 $2.71 $2,710
Ledoux Mark A CEO/Chairman February 23, 2026 Buy 750 $2.70 $2,025
Ledoux Mark A CEO/Chairman February 20, 2026 Buy 250 $2.66 $665
Ledoux Mark A CEO/Chairman February 19, 2026 Buy 1,500 $2.56 $3,840

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around December 11, 2008 estimated from the company's past filing pattern, not announced

  • September 22, 2008
  • August 8, 2008
  • October 15, 2007
  • September 28, 2007
  • April 30, 2007
  • January 24, 2007

Recent SEC filings

Data status

When each part of this page on Natural Alternatives International Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Natural Alternatives International Inc in brief

What does Natural Alternatives International Inc do?
Natural Alternatives International Inc is a US-listed company in the pharmaceuticals industry. Its financial year ends in June.
What is Natural Alternatives International Inc's stock ticker?
Natural Alternatives International Inc trades under the ticker NAII on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Natural Alternatives International Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Natural Alternatives International Inc reported revenue of $143M, 9.7% higher than a year earlier, according to its SEC filings.
What is Natural Alternatives International Inc's free cash flow?
Natural Alternatives International Inc's free-cash-flow margin is -8.9% of revenue over the trailing twelve months, ranking 52 of the 74 pharmaceuticals companies we cover.
Who are Natural Alternatives International Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Caldwell Sutter Capital, Inc., Dimensional Fund Advisors LP and Morgan Stanley. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Natural Alternatives International Inc buying back stock, and does it pay a dividend?
Natural Alternatives International Inc spent $89,000 on share repurchases over the trailing twelve months, and its diluted share count still rose 1.4% over the year.
What is Natural Alternatives International Inc's market cap?
On June 30, 2026, Natural Alternatives International Inc's market capitalisation was about $14.4M and net debt of $10.6M. Market figures come from third-party market data and may be delayed.
How much debt does Natural Alternatives International Inc have?
Natural Alternatives International Inc's debt-to-equity ratio is 20.4%, from its latest balance sheet (11.4% five years earlier). The financial health section below sets out its other solvency checks.
Who are Natural Alternatives International Inc's competitors?
In our Pharmaceuticals peer group, the companies closest to Natural Alternatives International Inc are Zevra Therapeutics, Inc., Heron Therapeutics, Inc., Niagen Bioscience, Inc., Amarin Corp plc\uk and Cronos Group Inc. The side-by-side comparison below sets their revenue, margins and growth against Natural Alternatives International Inc's.
Are insiders buying or selling Natural Alternatives International Inc stock?
Over the last 12 months, Natural Alternatives International Inc's directors and officers reported 14 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.